Apr 16, 2018 by Motley Fool StaffWhat Novartis Bought in AveXisNovartis’ $9.8 billion acquisition of AveXis signals some pretty exciting long-term focus in promising gene therapies.
Apr 16, 2018 by Motley Fool StaffWhat Incyte's Phase 3 Fail Means for Immuno-OncologyIncyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.
Apr 16, 2018 by Motley Fool StaffWhat's Next for Incyte?With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
Apr 16, 2018 by Motley Fool StaffThe Strange Tale of LongFinTrading in the fintech company's shares has been halted.
Apr 16, 2018 by Motley Fool StaffWalmart Makes a Bet on E-Commerce in IndiaThe retail giant is reportedly planning to buy a majority stake in Flipkart.
Apr 16, 2018 by Motley Fool StaffBad Guidance Sinks Bed Bath & BeyondThe troubled retailer’s stock hits a new low.
Apr 16, 2018 by Motley Fool StaffM&T Bank Corporation (MTB) Q1 2018 Earnings Conference Call TranscriptMTB earnings call for the period ending March 31, 2018.
Apr 16, 2018 by Motley Fool StaffBank of America Corporation (BAC) Q1 2018 Earnings Conference Call TranscriptBAC earnings call for the period ending March 31, 2018.
Apr 16, 2018 by Motley Fool StaffHas Estée Lauder Stock Flown Too Far, Too Fast?This multinational beauty powerhouse is trading at all-time highs, but the stock is not without its risks.
Apr 15, 2018 by Motley Fool StaffInfosys Ltd (INFY) Q4 2018 Earnings Conference Call TranscriptINFY earnings call for the period ending March 31, 2018.
Apr 15, 2018 by Motley Fool StaffWhy Estée Lauder Stock Is Gaining Momentum in 2018Accelerating top and bottom line growth has the market excited about this skincare giant.
Apr 14, 2018 by Motley Fool Staff2 Core Strengths Powering the Growth at Estée LauderThe multinational beauty powerhouse relies on smart distribution and acquisitions to enhance its bottom line.
Apr 13, 2018 by Motley Fool StaffWhat Happened With Incyte's IDO Inhibitor FlopInvestor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Apr 13, 2018 by Motley Fool StaffDelta Air Lines (DAL) Q1 2018 Earnings Conference Call TranscriptDAL earnings call for the period ending March 31, 2018.
Apr 13, 2018 by Motley Fool StaffWells Fargo & Company (WFC) Earnings Conference Call TranscriptWFC earnings call for the period ending March 31, 2018.
Apr 13, 2018 by Motley Fool StaffApogee Enterprises (APOG) Q4 2018 Earnings Conference Call TranscriptAPOG earnings call for the period ending March 3, 2018.
Apr 13, 2018 by Motley Fool StaffRite Aid (RAD) Q4 2018 Earnings Conference Call TranscriptRAD earnings call for the period ending March 3, 2018.
Apr 13, 2018 by Motley Fool StaffCitigroup Inc (C) Q1 2018 Earnings Conference Call TranscriptC earnings call for the period ending March 31, 2018.
Apr 13, 2018 by Motley Fool StaffPNC Financial Services Group, Inc. (The) (PNC) Q1 2018 Earnings Conference Call TranscriptPNC earnings call for the period ending March 31, 2018.
Apr 13, 2018 by Motley Fool StaffJ P Morgan Chase & Co. (JPM) Q1 2018 Earnings Conference Call TranscriptJPM earnings call for the period ending March 31, 2018.
